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ABSTRACT
Objectives: The aim of the study was to compare effects of addition of two methods of ductus venosus (DV) flow assessment: 
qualitative — the assessment of shape of the A-wave (positive or negative), and quantitative — based on the pulsatility 
index for veins (DVPI) to the basic screening for trisomy 21 at 11 to 13 + 6 weeks of pregnancy.
Material and methods: The ultrasound examination was performed in 8230 fetuses in singleton pregnancies at 11– 
–13 + 6 wks, as a part of a routine screening for chromosomal defects. In DV A-wave was assessed and DVPI was calculated. 
After the scan blood sample was taken for first trimester biochemistry (BC). Risk for chromosomal defects was calculated 
and high-risk patients were offered an invasive test for karyotyping. 
Results: Basic screening with following combination of markers: MA, NT and BC provided lowest detection rate (DR) 
87.50% for FPR = 6.94%. After adding qualitative DV A-wave assessment DR increased to 88.75% for FPR = 5.65%. The best 
DR = 93.75% for FPR = 5.55% was achieved when quantitative DVPI was added. The application of the Receiver Operating 
Curves curve confirmed validity of the addition of DV flow assessment to the screening model. The highest diagnostic 
power of the test was achieved when DVPI was added, with the ROC AUC of 0.974.
Conclusions: The assessment of DV flow performed at 11–13 + 6 weeks increases DR for trisomy 21 and reduces FPR. The 
screening model based on the quantitative DV flow analysis (DVPI) gives better results compared to the qualitative flow 
assessment. 
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INTRODUCTION
The ultrasound examination performed at 11 to 
13 + 6 weeks of pregnancy allows for the assessment of 
the fetal structure, but also identification of fetuses at in-
creased risk of chromosomal defects [1–3]. Nuchal trans-
lucency (NT) is considered to be the strongest marker of 
chromosomal defects, but in order to increase sensitivity 
and specificity some additional ultrasound markers are 
also assessed, including the nasal bone (NB), flow through 
the tricuspid valve (Tricuspid Regurgitation, TR), and flow 
through the ductus venosus (DV) [3, 4]. The use of the last 
marker is increasing in screening for chromosomal defects 
and cardiac defects [3, 5, 6]. There are two methods of the 
DV assessment: qualitative — the assessment of the shape 
of the A-wave (the atrial component of the waveform), 
and quantitative — DVPI based on the pulsatility index 
for veins (PIV) [5, 7, 8] The screening algorithm for triso- 
my 21 (Down’s Syndrome) involving maternal age (MA), NT, 
and first trimester biochemistry (BC) — serum free beta sub-
unit of chorionic gonadotropin (free β-hCG), and pregnancy-
associated plasma protein A (PAPP-A) levels expressed in 
MoMs — shows detection rate (DR) of 91% and 3% false 
positive rate (FPR). According to previous studies, adding 
the assessment of the DV increases DR of the test to 96% 
whereas FPR remains at the level of 3% [5, 8].
OBJECTIVES
The aim of the study was to evaluate and compare quali-
tative and quantitative methods of assessment of blood flow 
in the DV as additional parameters in screening for trisomy 
21 at 11 to 13 + 6 wks.
MATERIAL AND METHODS
The ultrasound examinations (Voluson Expert VE 
730 and Voluson Expert E8, General Electric) was performed 
in 8230 singleton pregnancies by doctors certified by the 
Fetal Medicine Foundation (FMF), as a part of a routine 
screening for chromosomal defects at 11 to 13 + 6 wks, 
between 2010 and 2014. Given the methodology of this 
study (retrospective, anonymized, non-interventional), as 
per the local rules, there was no need for review by a re-
search ethics board.
The following were assessed: crown rump length (CRL), 
fetal heart rate (FHR), NT, and DV flow analysed using two 
different methods. The first method involved the assess-
ment of presence/absence of the A-wave, and the second 
was based on the measurement of DVPI according to FMF 
rules. The fetal anatomy was assessed to exclude structural 
abnormalities (according to International Society of Ultra-
sound in Obstetrics and Gynecology guidelines). 
Maternal blood samples were collected from all patients 
for the assessment of the serum level of the free β-hCG 
and PAPP-A (FMF-certified: Delfia Express, Perkin-Elmer), 
subsequently expressed in MoMs for risk calculation (first 
trimester biochemistry — BC). The risk for trisomy 21 was 
calculated using the FMF-certified software (Astraia, Astraia 
Software Gmbh). 
We analysed three models in screening for trisomy 
21 — first: NT + BC, second: NT + BC + DV A-wave, and third: 
NT + BC+ DVPI. The cut off for invasive testing was 1:300 in 
all models. In high-risk patients, an invasive procedure (am-
niocentesis) was performed for fetal karyotyping. Where the 
karyotype result was not available, healthy neonates were 
assessed phenotypically (follow-up).
The statistical analysis
The XLSTAT software for Microsoft Excel was used for the 
statistical analysis. Data were assessed for normality of the 
distribution using Shapiro-Wilk test, and the U Mann-Whitney 
test was used for non-normal distribution. Qualitative param-
eters were analysed using the Chi2 test. The ROC curves were 
used to determine the diagnostic threshold values. Sensitivity 
and specificity were calculated for each threshold value. In 
all tests the statistical significance was assessed by p value, 
which was considered significant if lower than 0.05.
RESULTS
7554 fetuses were included in the final analysis. Remain-
ing 676 cases with other chromosomal defects, or normal 
karyotype and congenital abnormalities, or because of be-
ing lost to follow-up were excluded from the study. The 
gestational age was determined based on the CRL meas-
urement. Among 7554 patients, trisomy 21 was found in 
80 cases (1.06%). The remaining 7474 fetuses presented 
normal phenotype (98.94%). The characteristics of the study 
population are shown in Table 1.
An abnormal DV A-wave was found in 258 (3.45%) of 
fetuses with a normal karyotype and in 38 (47.5%) with 
trisomy 21 (p < 0.0001). 
The highest DR (93.75%) was achieved when DVPI cal-
culation was introduced to the model. When determination 
of presence/absence of DV A-wave was added, DR was sig-
nificantly lower (88.75%). The lowest DR (87.5%) was found 
in the basic model without DV flow assessment. 
In NT + BC + DVPI model for the 1:300 and 1:200 cut-offs 
for high risk for trisomy 21 the same DR was achieved 
(93.75%), but for the 1:200 cut-off FPR was lower (reduc-
tion from 5.55% to 3.72%). Interestingly in NT + BC + DV 
A-wave model for the 1:300 and 1:200 cut-offs, DR was also 
the same (88.75%) and for the 1:200 cut-off FPR was lower 
(reduction from 5.65% to 3.88%). For cut-offs of 1:100 and 
1:50 DRs were markedly worse (Tables 2–4).
The introduction of the DVPI assessment allowed cre-
ating the best model with DR of 93.75% and FPR 5.55%. 
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Increasing the risk cut-off to 1:200 reduces FPR to 3.72% 
without changing DR (Table 4). 
The application of the ROC curve for the analysis con-
firmed validity of addition of the qualitative and quantitative 
DV markers. The diagnostic power of the test was highest 
for DVPI, with the ROC AUC value of 0.974 (Figures 1–3). 
Table 5 presents results of comparison of the ROC curves 
depending on the additional DV marker used.
DISCUSSION
The main goal of non-invasive prenatal screening for 
Down’s syndrome is selection of high-risk patients who should 
be offered an invasive testing. The main challenge in screening 
is achieving the highest possible DR and lowest FPR [3, 9]. The 
addition of DV flow analysis, after obtaining trisomy 21 risk 
Table 1. Characteristics of the study population
Variable
Mean SD Minimum Median Maximum
p
N T21 N T21 N T21 N T21 N T21
Maternal age (years) 32.58 29.38 5.17 4.95 14.00 22.00 34.00 28.00 46.00 43.00 < 0.0001
CRL [mm] 62.82 63.83 8.37 10.82 45.00 45.00 62.70 64.50 84.00 84.00 < 0.0001
NT [mm] 1.75 4.87 0.48 1.82 0.80 1.80 1.70 4.85 10.00 8.02 < 0.0001
FHR (bpm) 160.47 160.91 6.01 8.48 122.00 145.00 161.00 162.00 206.00 181.00 < 0.0001
β-hCG (MoM) 1.34 1.76 0.92 0.89 0.09 0.20 1.07 1.75 7.70 4.37 < 0.0001
PAPP-A (MoM) 1.07 0.88 0.62 0.76 0.12 0.16 0.97 0.69 9.74 4.49 < 0.0001
DV-PI 1.053 1.764 0.31 0.68 0.47 0.8 1.00 2.0 3.1 2.9 < 0.0001
CRL — crown rump length; NT — nuchal translucency; FHR — fetal heart rate; β-hCG — free β subunit of chorionic gonadotropin; PAPP-A — pregnancy-associated 
plasma protein A; MoM — median; DV-PI — pulsatility index for the ductus venosus
Table 2. The analysis of DR and FPR in NT + BC model
Risk 1:300 1:200 1:100 1:50
DR (%) 87.50 86.25 83.75 81.25
FPR (%) 6.94 5.3 2.6 1.30
DR — sensitivity; FPR — number of false positive results
Table 3. The analysis of DR and FPR in NT + BC + DV A-wave model
Risk 1:300 1:200 1:100 1:50
DR (%) 88.75 88.75 85.00 57.50
FPR (%) 5.65 3.88 2.44 1.77
DR — sensitivity; FPR — number of false positive results
Table 4. The analysis of DR and FPR in NT + BC + DVPI model
Risk 1:300 1:200 1:100 1:50
DR (%) 93.75 93.75 86.25 61.25
FPR (%) 5.55 3.72 2.37 1.8
DR — sensitivity; FPR — number of false positive results
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Figure 1. The ROC curve for NT + BC model
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Figure 2. The ROC curve for NT + BC + DV A-wave model
calculated based on NT + BC, allows for more precise separa-
tion of the group with a high trisomy 21 risk, as compared 
to the method based on NT + BC only [3, 5]. Abnormal DV in 
trisomy 21 is assumed to be indicative of impaired diastolic 
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function (ventricular filling) due to volume overload [11]. 
Interestingly, abnormal DV Doppler test in euploid fetuses in 
the first trimester is associated with poor obstetric outcomes, 
including higher rate of placental abruption, preterm delivery, 
lower birth weight and lower Apgar scores [12].
In trisomy 21 screening based on NT + BC, DR is approxi-
mately 90%, with FPR of about 3–5% [3, 10]. In our data for 
NT + BC, DR is 87%, and FPR — 6.94%, for the cut-off risk at 
1:300. And the qualitative assessment of flow (DV A-wave) 
increases DR to 88.75%, with FPR of 5.65%. Those are slightly 
better results compared to the trisomy 21 risk assessment 
based on NT + BC only. In case of the analysis of presence 
of the DV A wave, Nicolaides reports DR of 91.93%, with 
FPR of 2.5% [13, 14].
Results of this study demonstrate that it is possible to 
achieve DR of 93.75%, with simultaneous reduction of FPR to 
5.55%, with DVPI analysis. Further reduction of FPR to 3.75% 
can be achieved increasing high-risk cut-off form 1:300 to 
1:200 without change in DR. Mainz et al. noted DR at the 
level of 95%, with FPR of 2.9%. In our study, the abnormal DV 
A-wave was observed in 258 (3.45%) of fetuses with a normal 
karyotype and in 38 (47.5%) with trisomy 21 (p < 0.0001). 
Literature data indicate a broad scope of presence of the 
abnormal A-wave in DV 7.7% — 38.3% in trisomy 21 cases 
[15, 16]. A similarly broad scope of presence of the reversed 
DV A-wave was observed in normal fetuses (2.0–13.0%). 
Maiz and Nicolaides reported that an abnormal flow in the 
DV was observed in 69.1% of trisomy 21 fetuses, and in 3.7% 
of chromosomally normal fetuses [5, 17]. First reports of the 
use of the DV flow assessment in trisomy 21 screening have 
been published in 1990’s [16]. 
Undoubtedly, the addition of the qualitative assessment 
of the DV flow (DV A-wave) to the screening of trisomy 21 
improves its efficacy [10]. DVPI assessment not only in-
creases DR and decreases FPR in trisomy 21 screening, but 
also improves detection of congenital heart defects [18, 19]. 
Our results demonstrate that adding DVPI measurement in-
creases DR from 87.5% to 93.75%, with decrease of FPR from 
6.94% to 5.55%. Using the double-step screening model for 
trisomy 21 with DVPI analysis, Maiz et al. achieved the DR of 
93.5% and FPR of 1.63% [5]. 
Wagner et al. in a retrospective study compared DV as-
sessment in screening for trisomy 21 flow either as dichoto-
mous classification of the a-wave, as measurement of the DV 
PIV, or both. The DV a-wave was reversed in 2.3% and 66.1% 
in the euploid and trisomy 21 fetuses, respectively. The DV 
PIV measurements were above the 95th percentile in 8.3% 
and 77.2% the euploid cases and trisomy 21, respectively. 
They found that for a FPR of 3%, the DR for trisomy 21 based 
on maternal age, fetal NT, and DV flow was about 87% ir-
respective of whether DV is examined as a continuous or 
dichotomous variable [20]. In a study of the performance of 
the first trimester ultrasound screening for trisomy 21 with 
additional ultrasound parameters: nasal bone (NB), tricuspid 
flow (TF) and ductus venosus (DV) the authors found that DR 
is substantially higher if all three additional markers rather 
than just one are assessed [21]. The later clearly shows that 
quality ultrasound scan performed in specialized centers 
performs better in screening that basic ultrasound.
Our study shows that introducing the quantitative analy-
sis of the DV flow (DVPI) improves screening for trisomy 21 at 
11–13 + 6 wks based on assessment of nuchal translucency 
and first trimester biochemistry more than adding just the 
qualitative assessment of the DV flow (DV A-wave).
CONCLUSIONS
The assessment of the DV flow performed at 11– 
–13 + 6 wks increases detection rate and reduces false posi-
tive rate in screening for trisomy 21.
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Figure 3. The ROC curve for NT + BC + DVPI model
Table 5. Diagnostic values of assessed parameters based in the area under the curve for ROC
Risk calculation model Area under the curve (AUC) Standard error Confidence level (95%)
NT + BC 0.964 0.007 0.950–0.979
NT + BC + DV A-wave 0.968 0.007 0.954–0.982
NT + BC + DVPI 0.974 0.006 0.962–0.987
DV — ductus venosus; DVPI — ductus venosus pulsatility index
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The screening model based on the quantitative DV flow 
(DV PI) analysis gives better results as compared to the 
qualitative flow assessment (DV A-wave).
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